Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director | June 22, 2023 | June 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Taysha Gene Therapies, Inc.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2033-06-22 | Direct | 36,200 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 36,200 · Balance 36,200 F1: The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2023 Filed Jun 26, 2023 20:50 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 36,200 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-23-039732 · doc4.xml · derivative · entry 1 Reape Kathleen · CIK 0001832203 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,200 Underlying: Common Stock · 36,200 shares Expires 2033-06-22 F1 · derivative.exercise_date: The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:37 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-038687 · doc4.xml · derivative · entry 1 Reape Kathleen · CIK 0001832203 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2032-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:01 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $25.04 | $0.00 |
DisclosureSEC source: 0001209191-21-042106 · doc4.xml · derivative · entry 1 Reape Kathleen · CIK 0001832203 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:41 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001209191-20-060225 · doc4.xml · derivative · entry 1 Reape Kathleen · CIK 0001832203 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2030-11-23 F1 · derivative.exercise_date: The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.